Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of afamelanotide implants in solar urticaria
2008-002143-16Phase 3Terminated
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Mar 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in solar urticaria (SU) comparing Afamelanotide implant first with Placebo implant first (2 arms). Started Mar 2010; status: terminated.
02
Drugs
Afamelanotide
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on 2008-002143-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002143-16.